glp 1 and lightheadedness GLP‑1 headaches: why they happen what actually helps GLP‑1 and dizziness: causes, red

Regulatory approvals for obesity-specific indications and the shifting perception of obesity as a chronic medical condition rather than a lifestyle issue are further improving market momentum

The research was published Monday in The Lancet Diabetes & Endocrinology

The FDA has approved Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

This version had several advantages: once-weekly dosing stronger blood-glucose control noticeable weight loss in many patients Doctors began prescribing it more widely for people with type 2 diabetes AND obesity , and the medication started gaining attention

Acknowledgments The authors gratefully acknowledge the critical reviews and insights of Sarah Armstrong MD, Nancie MacIver MD PhD, and Lisa Rasbach PhD CPNP

Anxiety often goes unrecognized and undiagnosed, said Wellstar Physician Dr